Market Overview

Sobi Receives Approval From the FDA for Once-Daily Dosing Frequency of Orfadin® (nitisinone) for the Treatment of HT-1

Share:

- First and only nitisinone product approved for once daily use in
U.S., designed by Sobi to meet the changing needs of HT-1 patients
entering older childhood, adolescence and adulthood -

Sobi, a pioneering global biopharmaceutical company dedicated to rare
and difficult-to-treat diseases, has received approval from the U.S.
Food and Drug Administration (FDA) for a reduced dosing frequency for
Orfadin® (nitisinone) from twice daily to once daily in
patients 5 years of age and older.

Orfadin is approved in combination with dietary restriction of tyrosine
and phenylalanine for people with hereditary tyrosinemia type 1 (HT-1),
a rare genetic disorder that can cause liver, renal and neurological
complications. The reduced dosing frequency is approved for use in
patients 5 years of age and older who have undetectable serum and urine
succinylacetone concentrations after a minimum of 4 weeks on a stable
dosage of nitisinone. A once-daily dosing option was also approved by
the European Commission in the beginning of 2017.

"We are very happy to receive the approval by the FDA of the new dosing
frequency for Orfadin. Orfadin is the first nitisinone product approved
for once daily use in the U.S. This is an important step towards
reducing the treatment burden of people with HT-1 and it follows Sobi's
introduction of Orfadin 20mg capsules and Orfadin oral suspension," says
Milan Zdravkovic, Senior Vice President, Chief Medical Officer, and Head
of Research & Development at Sobi.

Orfadin is the first nitisinone product approved in the U.S. and Europe.
The U.S. approval of the once-daily formulation was based on the results
of a clinical study in 16 HT-1 patients, comparing a 4-week once-daily
and 4-week twice daily dosing regimen. The study showed comparable
blood-levels of nitisinone for these two regimens. The original approval
in the U.S. in 2002 was based on an open-label study of 207 HT-1
patients, in which patients younger than 2 months of age who were
treated with dietary restrictions and Orfadin experienced 2- and 4-year
survival probabilities of 88% and 88%, respectively. Data from
historical controls showed that patients treated with dietary
restriction alone had 2- and 4-year survival probabilities of 29% and
29%, respectively. For patients presenting between 2 and 6 months of age
who were treated with dietary restrictions and Orfadin, 2- and 4-year
survival probabilities were 94% and 94%, respectively. Data for
historical controls showed that patients treated with dietary
restriction alone had 2- and 4-year survival probabilities of 74% and
60%, respectively. The most common adverse reactions (incidence >2%)
seen with Orfadin use are hepatic neoplasm, liver failure,
thrombocytopenia, leucopenia, visual system complaints including
conjunctivitis, corneal opacity, keratitis, and photophobia. Please see
important safety information below.

"Between dietary restrictions and pharmaceutical treatment, HT-1
patients and their families have a lot to deal with every day, and I
applaud Sobi for recognizing that and for introducing new dosing options
like once-daily Orfadin for patients 5 years of age and older," said Jon
Miller, President of the Network of Tyrosinemia Advocates (NOTA). "My
son has HT-1, and Sobi has been a partner to our family through the
years, providing many forms of support including multiple dosing
alternatives, access to nurses, educational materials and assistance
with navigating insurance issues."

"Although HT-1 is a very rare disorder, affecting only an estimated 150
patients in the United States, it is potentially fatal without
nitisinone treatment," said Can Ficicioglu, M.D., Ph.D., Director of the
Newborn Metabolic Screening Program and the Lysosomal Storage Diseases
Program at Children's Hospital of Philadelphia. "Before the introduction
of Orfadin, fewer than one-third of infants diagnosed with HT-1 before
two months of age lived past their second birthday. Today, many HT-1
patients have entered adolescence or even adulthood, requiring
increasing doses, so I appreciate that Sobi is providing new dosing
options like once-daily Orfadin."

About Orfadin®

People with hereditary tyrosinemia type 1 (HT-1) have problems breaking
down an amino acid called tyrosine. Toxic by-products are formed and
accumulate in the body, which can cause liver, renal and neurological
complications. Approximately 1,000 persons worldwide are identified as
living with HT-1 today.

Orfadin® (nitisinone) blocks the breakdown of tyrosine,
thereby reducing the amount of toxic tyrosine by-products in the body.
Patients must maintain a special diet in combination with Orfadin
treatment as tyrosine is not adequately broken down. Orfadin is a
proprietary product and is developed and made available globally by Sobi.

For full U.S. prescribing information, please visit www.orfadin.com.

Indication and Usage

Orfadin is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate
dioxygenase indicated for use as an adjunct to dietary restriction of
tyrosine and phenylalanine in the treatment of hereditary tyrosinemia
type 1 (HT-1).

Important Safety Information

  • Tyrosine levels can increase in the blood if you do not restrict
    tyrosine and phenylalanine in your diet while taking Orfadin. Too much
    tyrosine in the blood can cause serious eye problems or other
    complications
  • Do not adjust your Orfadin dosage in order to lower the tyrosine
    levels in the blood.
  • A reduction in the number of white cells and platelets in the blood
    have been observed during treatment with Orfadin. Your platelet and
    white blood cell counts should be monitored regularly during Orfadin
    treatment.
  • The most common adverse reactions to taking Orfadin are liver cancer,
    liver failure, low platelets or white cells in the blood, and
    complaints related to the eyes, including conjunctivitis, corneal
    opacity, inflammation of the cornea, and extreme sensitivity to light.
  • Tell your physician promptly if you have unexplained eye symptoms,
    rash, jaundice (yellowing of the skin or whites of the eyes) or
    excessive bleeding.
  • Use Orfadin during pregnancy only if the potential benefit justifies
    the potential risk to the fetus.
  • Nursing women should discontinue either Orfadin or breast-feeding
    based on the recommendation of your healthcare professional.

For full prescribing information, please visit www.orfadin.com

About Sobi™

Sobi is an international specialty healthcare company dedicated to rare
diseases. Sobi's mission is to develop and deliver innovative therapies
and services to improve the lives of patients. The product portfolio is
primarily focused on Haemophilia, Inflammation and Genetic diseases.
Sobi also markets a portfolio of specialty and rare disease products
across Europe, the Middle East, North Africa and Russia for partner
companies. Sobi is a pioneer in biotechnology with world-class
capabilities in protein biochemistry and biologics manufacturing. In
2016, Sobi had total revenues of SEK 5.2 billion (USD 608 M) and about
760 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More
information is available at www.sobi.com.

View Comments and Join the Discussion!
 
Loading...